Inmunotherapy: Recognising and Treating Adverse Effects

I. Ruiz Santos, E. Mateos Egido, A. Domínguez Fariña, G. Avanzini Martinez, F. Madriñán Gonzalez, M. Lombardero Pin
Complejo Hospitalario Universitario Insular-Materno Infantil, Pharmacy, Las Palmas de Gran Canaria, Spain

Background and objectives

- Inmunotherapy have changed the landscape of cancer treatment for the last years. Among them, immune checkpoint inhibitors are increasingly used for certain cancers; however, this has resulted in increased reports of immune-related adverse events (irAEs).
- The objective was to identify the irAEs, their gravity, management and appearance time, according to treatment and pathology.

Material and methods

- 612 patients
- 52 irAE
- 61 years old (39-88)
- 67 ± 10 kg
- 227 Days until appearance

Results

- Type of cancer
- Toxicity grade
- Treatment
- Toxicity

Conclusion and relevance

Inmunotherapy drugs can occasionally develop some adverse effects. In our study the most common was nephrotoxicity due to pembrolizumab. Despite that, most patients continued treatment once the adverse event was solved. As reported in some guides, the majority of irAEs were solved using methylprednisolone. More studies are needed based on obtaining more specific conclusions.

Contact us: iruisana@gobiernodecanarias.org